We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $9.59B
1-Year Est. Return 113.36%
This Fund
S&P 500
This Quarter Est. Return
+6.55%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$8.48B
AUM Growth
+$646M
Cap. Flow
-$743M
Cap. Flow %
-8.77%
Top 10 Hldgs %
50.85%
Holding
160
New
9
Increased
15
Reduced
10
Closed
78

Top Buys

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$83.8M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$82.1M
3
PFE icon
Pfizer
PFE
+$80.9M
4
GMAB icon
Genmab
GMAB
+$73.8M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$59.1M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$76.2M
2
RVMD icon
Revolution Medicines
RVMD
+$60.3M
3
PHR icon
Phreesia
PHR
+$33.8M
4
VTR icon
Ventas
VTR
+$27.4M
5
SYRE icon
Spyre Therapeutics
SYRE
+$23.3M

Sector Composition

Rank Sector Weight
1 Healthcare 84.65%
2 Miscellaneous 15.35%
3 Consumer Discretionary 0%
4 Consumer Staples 0%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDLN
151
Medline Inc
MDLN
$30.4B
– –
-260,000
Closed -$10.9M
3 4 5 6
7

Similar funds

OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
MSE
MUFG Securities EMEA London, United Kingdom $9.53B AUM 52.96% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
A
Allianz Munich, Germany $9.48B AUM 23.58% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Deerfield Management's Q1 2026 Portfolio in Review

As of Q1 2026, Deerfield Management held 160 positions worth $8.48B, up 8.3% from $7.83B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Deerfield Management withdrew a net $743M in Q1 2026, closing 78 positions and reducing 10 holdings. Its most notable exit was Phreesia, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 87% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

Against the trend, Deerfield Management opened a new position in Syndax Pharmaceuticals worth $88.3M.

  • Deerfield Management's largest Q1 2026 buy was Syndax Pharmaceuticals: 3,779,900 shares worth $88.3M.
  • Deerfield Management added most to Inspire Medical Systems in Q1 2026, an estimated $83.8M increase.
  • Deerfield Management's biggest Q1 2026 reduction was Neurocrine Biosciences, cutting an estimated $76.2M.
  • Deerfield Management fully exited Phreesia in Q1 2026, selling an estimated $33.8M.
  • Deerfield Management's ten largest holdings make up 51% of its $8.48B portfolio in Q1 2026.
  • Deerfield Management opened 9 new positions and closed 78 in Q1 2026.
  • Deerfield Management's portfolio value rose 8.3% quarter-over-quarter to $8.48B.

Based on Deerfield Management's 13F filing for Q1 2026, filed 15 May 2026.